Results 81 to 90 of about 45,197 (186)

Natural Products Exhibit Therapeutic Potential in Treating Rheumatoid Arthritis by Targeting the PI3K/Akt Signaling Pathway

open access: yesPhytotherapy Research, EarlyView.
This review summarizes how natural products, mainly including flavonoids, terpenoids, alkaloids, and polyphenols alleviate RA via PI3K/Akt pathway, regulating inflammation, proliferation, apoptosis, angiogenesis, and osteoclast differentiation. The figure was created by Figdraw (https://www.figdraw.com/#/).
Haishuo Ren   +10 more
wiley   +1 more source

Impact of sleep insufficiency and recovery on cancer development

open access: yesSleep Research, EarlyView.
Abstract Sleep plays a critical role in overall health, and modern lifestyles, such as shift work and late‐night activities, can significantly impact sleep condition. Insufficient sleep has been associated with various adverse health outcomes, including an increased risk of tumor development.
Xiaxi Li, Chuanyuan Li, Yi Zhang
wiley   +1 more source

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions

open access: yesBiomolecules
Poly(ADP-ribose) polymerases (PARPs) are crucial nuclear proteins that play important roles in various cellular processes, including DNA repair, gene transcription, and cell death.
Denys Bondar, Yevgen Karpichev
doaj   +1 more source

A single‐molecule prodrug synergistically suppresses MYC‐amplified osteosarcoma through sequential nitric oxide release and photodynamic therapy

open access: yesSmart Molecules, EarlyView.
A cascade‐responsive small‐molecule prodrug (DHU‐NO3) sequentially releases methylene blue (triggered by reactive oxygen species) and nitric oxide (controlled by 405 nm light), enabling precise spatiotemporal coordination of photodynamic therapy and NO gas therapy to effectively inhibit MYC‐amplified osteosarcoma growth.
Shuxin Peng   +12 more
wiley   +1 more source

Differentiating high‐ and low‐grade serous ovarian carcinoma using radiomics: a pilot study

open access: yesUltrasound in Obstetrics &Gynecology, EarlyView.
ABSTRACT Objective To identify ultrasound‐based radiomics features capable of distinguishing between high‐grade serous ovarian carcinomas (HGSC) and invasive low‐grade serous ovarian carcinomas (LGSC), and to develop machine‐learning models that include radiomics features to discriminate between the two.
F. Ciccarone   +17 more
wiley   +1 more source

CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib

open access: yesBritish Journal of Haematology, EarlyView.
Summary Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood.
Omar Faruq   +6 more
wiley   +1 more source

Photothermal-driven sequential immunotherapy overcomes resistance to PARP inhibition in Brca1-deficient triple-negative breast cancer

open access: yesActa Pharmaceutica Sinica B
Triple-negative breast cancer (TNBC) faces formidable clinical challenges due to target scarcity and a profound immunosuppressive microenvironment, necessitating innovative therapeutic strategies.
Zhenyu Xu   +11 more
doaj   +1 more source

Comparative effectiveness of apalutamide‐, abiraterone‐, and enzalutamide‐based doublets in mHSPC

open access: yesBJU International, EarlyView.
Background and Objective Treatment of metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved from androgen‐deprivation therapy (ADT) alone to combination therapy with androgen receptor pathway inhibitors. Although apalutamide (APA), abiraterone (ABI), and enzalutamide (ENZA) improve outcomes when added to ADT, direct comparative trials ...
Anikó Katalin Valikovics   +9 more
wiley   +1 more source

Exceptional synergistic response of PARP inhibitor and immune checkpoint inhibitor in esophageal adenocarcinoma with a germline BRCA2 mutation: a case report

open access: yesTherapeutic Advances in Medical Oncology
Immune checkpoint inhibitors (ICIs) and poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in various tumors. A significant therapeutic challenge with either ICIs or PARP inhibitors as monotherapy is treatment failure from intrinsic ...
Himil Mahadevia   +5 more
doaj   +1 more source

Gliomas with pleomorphic and pseudopapillary features (GPAP) are circumscribed tumors with targetable mutations, prolonged survival, and frequent tumor predisposition

open access: yesBrain Pathology, EarlyView.
DNA methylation profiling identifies GPAP as a distinct circumscribed glioma with a characteristic expansive, multicystic radiological appearance, pleomorphic and pseudopapillary histology, a recognizable CNV profile, druggable molecular alterations, and recurrent cancer predisposition syndromes.
Alberto Picca   +35 more
wiley   +1 more source

Home - About - Disclaimer - Privacy